REAL-WORLD UTILIZATION, CMV REACTIVATION OUTCOMES AND SURVIVAL ANALYSIS OF BIOEQUIVALENT GENERIC LETERMOVIR PROPHYLAXIS IN INDIAN ALLOGENEIC HSCT RECIPIENTS: DEFENDER STUDY (EBMT 2026) - Feb 7, 2026 - Abstract #P156; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Real-world use of bioequivalent generic Letermovir demonstrates high tolerability, favourable CMV-infection-free survival, low breakthrough infection rates, and excellent adherence across varied transplant settings in India. These findings support its continued integration into routine CMV prophylaxis strategies for allo-HSCT recipients."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Hematological Disorders • Infectious Disease • Sickle Cell Disease
|
|
Gaurav Kharya1; Sameer Ramesh Melinkeri2; Santanu Sen3; Nataraj KS4; Kasi Viswanathan5; Rajat Bhattacharyya6; Nidhi Jain7; Chintan Vyas8; Vaibhav Chadha1; Garima Nirmal1; Abhijit Baheti2; Suyash Bharat9
|